Literature DB >> 11261596

Disopyramide block of K(ATP) channels is mediated by the pore-forming subunit.

B J Zünkler1, S Kühne, I Rustenbeck, T Ott, A G Hildebrandt.   

Abstract

The class Ia antiarrhythmic agent disopyramide blocks native ATP-sensitive K+ (K(ATP)) channels at micromolar concentrations. The K(ATP) channel is a complex of a pore-forming inwardly rectifying K+ channel (Kir6.2) and a sulfonylurea receptor (SUR). The aim of the present study was to further localize the site of action of disopyramide. We have used a C-terminal truncated form of Kir6.2 (Kir6.2delta26), which--in contrast to Kir6.2--expresses independently of SUR. Kir6.2delta26 channels were expressed in African green monkey kidney COS-7 cells, and enhanced green fluorescent protein (EGFP) cDNA was used as a reporter gene. EGFP fluorescence was visualized by a laser scanning confocal microscope. Disopyramide applied to the cytoplasmic membrane surface of inside-out patches inhibited Kir6.2delta26 channels half-maximally at 7.1 microM (at pH 7.15). Lowering the intracellular pH to 6.5 potentiated the inhibition of Kir6.2delta26 channels by disopyramide. These observations suggest that disopyramide directly blocks the pore-forming Kir6.2 subunit, in particular at reduced intracellular pH values that occur under cardiac ischaemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11261596     DOI: 10.1016/s0024-3205(00)00486-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Mechanism of terfenadine block of ATP-sensitive K(+) channels.

Authors:  B J Zünkler; S Kühne; I Rustenbeck; T Ott
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta-cell KATP channels and stimulate insulin secretion; statins as a test case.

Authors:  Joana Real; Caroline Miranda; Charlotta S Olofsson; Paul A Smith
Journal:  Endocrinol Diabetes Metab       Date:  2018-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.